WXXWY News and Press, Wuxi Biologics Cayman Inc ADR From 11/13/21

UBS highlights its picks in its four next-big-thing sectors: Greentech, 5G+, Fintech and Healthtech. "While this is a longer-term focus, we see attractive investment opportunities in the short to medium term whereby companies benefit from significant fiscal spending following the pandemic as ...

WuXi Biologics Launches a New GMP Commercial Drug Product Facility PR Newswire Enhances drug product services for projects at various stages, with an emphasis on late and commercial stage production Increases up to 60 million vials for commercial drug production pe...

Harding Loevner is an investment manager that invests primarily in publicly traded global equities. We were founded in 1989 by former managers for the Rockefeller family. Harding Loevner is a Delaware limited partnership. We operate independently of Affiliated Managers Group. The Glob...

WuXi Biologics is the largest biologics outsourcing company in China, and among the top three industry players in the world. The key risks for the stock are geopolitical tensions, policy risks in China, and weaker-than-expected profitability going forward. WuXi Biologics trades at...

WuXi Biologics Reports Strong 2021 Interim Results PR Newswire Revenue Increases by 126.7% Y-o-Y to RMB4,406.8 Million Gross Profit Grows by 191.7% Y-o-Y to RMB2,296.8 Million Adjusted Net Profit Attributable to Owners of the Company Increases...

The rapidly evolving regulatory landscape in China has persistently populated financial market headlines this summer. The cost of raising a larger family can be daunting, particularly as it relates to the “three mountains” of costs associated with childcare – educ...

WuXi Biologics'  (OTCPK:WXXWY) Biosafety Testing facility in Suzhou, China has received its second GMP certificate from the European Medicines Agency (EMA). The Biosafety Testing facility received its first EMA GMP certificate just over a year ago. The team offers cell line characterizat...

WuXi Biologics Biosafety Testing Facility Received Second EMA GMP Certificate PR Newswire SUZHOU, China , Aug. 2, 2021 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, announced ...

It was an excruciating week of a severe emotional storm with the share prices undergoing a rollercoaster ride. A deluge of news, speculations, and commentaries overwhelmed the mind. The massive and synchronized sell-off of Chinese equities was akin to a Golden Slam for the critics. It...

WuXi Biologics Received Commercial Manufacturing License from German Health Authorities for its German Drug Product Facility PR Newswire First GMP manufacturing authorization outside of China , validating WuXi Biologics' world-class quality system Only 12 month...